Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099130 | 0.92 | TACR1 (0.79) | TACR1 | |
| SCHEMBL6100555 | 0.92 | TACR1 (0.79) | TACR1 | |
| SCHEMBL6098193 | 0.90 | TACR1 (1.00) | TACR1 | |
| SCHEMBL6098196 | 0.90 | TACR1 (1.00) | TACR1 | |
| Hydrochloric Acid SCHEMBL6133200 | 0.89 | TACR1 (0.66) | TACR1 | |
| Hydrochloric Acid SCHEMBL6133117 | 0.89 | TACR1 (0.66) | TACR1 | |
| SCHEMBL6877383 | 0.87 | TACR1 (1.00) | TACR1 | |
| SCHEMBL6877389 | 0.87 | TACR1 (1.00) | TACR1 | |
| SCHEMBL6101280 | 0.86 | TACR1 (0.82) | TACR1 | |
| SCHEMBL6098093 | 0.86 | TACR1 (1.00) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094779-B2 | Piperazine oxime dervatives having NK-1 receptor antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-08-22 | — | — | US | disclosed |
| EP-1406894-B1 | PIPERAZINE OXIME DERIVATIVES HAVING NK-1 RECEPTOR ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2004-12-22 | — | — | EP | disclosed |
| US-20040176389-A1 | Piperazine oxime dervatives having nk-1 receptor antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-09-09 | — | — | US | disclosed |
| EP-1406894-A1 | PIPERAZINE OXIME DERIVATIVES HAVING NK-1 RECEPTOR ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003006459-A1 | PIPERAZINE OXIME DERIVATIVES HAVING NK-1 RECEPTOR ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176389-A1 | Piperazine oxime dervatives having nk-1 receptor antagonistic activity | TACR2, OPRK1, TACR1 | TACR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.